Department of Neuroscience


Neuroscience
Home > People > Joint Appointment Faculty > E. Antonio Chiocca, M.D., Ph.D.
 
People
Faculty
Joint Appointment Faculty
Hojjat Adeli, Ph.D.
Rene Anand, Ph.D.
Michele D. Basso, Ph.D.
John P. Bruno, Ph.D.
E. Antonio Chiocca, M.D., Ph.D.
Matthew John During, M.D., D.Sc.
Heithem M. El-Hodiri, Ph.D.
Mireia Gurau-de-Arellano, PhD
Charles W. Hall, Jr. M.D., Ph.D.
Andrew T. E. Hartwick, Ph.D.
M. Scott Herness, Ph.D.
Lyn B. Jakeman, Ph.D.
Brian K. Kaspar, Ph.D.
Sandra K. Kostyk, M.D., Ph.D.
Benedetta Leuner, Ph.D.
Amy E.Lovett-Racke, Ph.D.
Ulysses J. Magalang, M.D.
David Pitt, M.D.
Xin-An Pu, Ph.D.
Michael K. Racke, M.D.
Ali R. Rezai, M.D.
Andrej Rotter, Ph.D.
Joseph E. Steinmetz, Ph.D.
Bruce D. Trapp, Ph.D.
Gary L. Wenk, Ph.D.
Emeritus Faculty
Administrative Staff
Graduate Students
Postdoctoral Researchers/Fellows
Scientific Staff

E. Antonio Chiocca, M.D., Ph.D.


Chairman, Department of Neurological Surgery
Dardinger Family Professor of Oncologic Neurosurgery
Physician Director, OSUMC Neuroscience Signature Program
Co-Director, Dardinger Center for Neuro-Oncology and Neurosciences
Co-Director, Viral Oncology Program of the Comprehensive Cancer Center

N-1021 Doan Hall
410 W. 10th Avenue
Columbus, OH 43210

Phone  (614) 293-9312
Email: E.Chiocca@osumc.edu

 

 

MAJOR RESEARCH INTERESTS

• Biologic therapies and applications to disorders of the central nervous system
• Functional genomics in brain tumors
• Immune responses to gene delivery vehicles

DESCRIPTION OF RESEARCH

Biologic advances increasingly enable major technological innovations in the treatment of disorders of the central nervous system (CNS). Stem cell biology, interactions between viral and tumor cell life cycles, and definition of gene expression profiles in tumors represent fields of research for possible therapy.

Currently active research areas include:
1) engineering more efficient "tumor-killing" vectors
2) finding and testing novel prodrug/gene therapy strategies
3) defining more selective oncolytic viruses
4) characterizing the ability of bone marrow stem cells to “transdifferentiate” into tumor blood vessels or neurons in response to environmental stimuli
5) defining the role of the immune response in vector delivery of therapeutic molecules in tumors and in animal models of cerebral ischemia
6) developing models of gene transfer to ameliorate cerebrovascular ischemia; and
7) conducting functional genomic studies of neurodegenerative disease using our iBAC system